Supriya Lifescience Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/r7p4gjgr46enka940lcd0hcm.pdf

Key Takeaways


Margin Bridge: The Quarter’s Decline and the Full-Year Bet

Saloni Wagh: "If you actually have attended our earnings call for the last four, five quarters plus you will know that we have corrected our guidance post our impact of the China business in the last financial year. Since then we have corrected our margin guidance to be 28% to 30% which we have maintained and that is the margin that you will see also for the first 6 months."

Growth Drivers: Volume, Basket Expansion, and CDMO


LatAm Regulatory Opportunity: A Structural Shift

Satish Wagh: "The new regulated market is coming up, which is large in Brazil. People are ignoring that Brazil was catered for last 40 years by China, but all Chinese manufacturer was supplied without GMP standard, GMP documentation and for the first time the government of Brazil has come in 2022 in force that any supplier would like to change the vendor. They should come with the GMP certification from that company."

Innovation Pipeline: Early-Stage, Patent-Protected

Saloni Wagh: "There is no product of its time globally, and even for the gel, it is an extremely innovative product which helps in wound healing and scar free wound healing again no significant competitors globally for both the products."

China: Stabilized but Constrained

Satish Wagh: "The day you focus more and more in China, I'm sure you all are aware we are reading in the newspaper anti-dumping duties will be put on the product and there will be no say in the future."

Capex and Capacity: Two Plants, ~₹100 Crores


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth20–24% YoY overall growthFull year FY24
EBITDA margin28–30% full-year marginFull year FY24
Module-E commissioningCommissioning, then validations, then commercial operationsMarch–April 2024
Ambernath plant commercial productionCommercial production startMay 2024 onwards
DSM-Firmenich CDMO commercial volumesCommercial volumes beginNext quarter (Q3 FY24)
Broader CDMO commercial contributionCDMO pipeline begins contributing commercially9–12 months
Plasma nutrition commercial volumesGood commercial volume anticipated6–9 months
New product CEPs (6–8 products)CEPs awaited for products targeting regulated markets6–9 months
Oral cancer kit and wound gel commercializationFull project commercializationAt least 3 years
FY24 capex~₹100 crores (₹50 crores spent in H1)Full year FY24

Key Metrics

MetricQ2 FY24
Revenue from operations₹140 crores, vs ₹112 crores in Q2 FY23
H1 FY24 revenue from operations₹272 crores, vs ₹214 crores in H1 FY23
EBITDA₹32 crores, vs ₹29 crores in Q2 FY23
EBITDA margin22.7%, vs 25.5% in Q2 FY23
H1 FY24 EBITDA margin28%, same as H1 FY23
Profit before tax₹30 crores, vs ₹27 crores in Q2 FY23
PAT₹24 crores, vs ₹17 crores in Q2 FY23
PAT margin17%
Revenue growth guidance20% to 25% overall growth over last year
EBITDA margin guidance28% to 30% for the full year
Export share81% of turnover
Regulated market share46% of sales
India share~19% of sales
Capacity utilization72% to 73% during Q2
Inventory days158 days, reduced from prior levels
One-off expenses in the quarter~₹3 crores to ₹4 crores, including GST audit, pre-import case interest, and FDA audit preparation
CAPEX, H1 FY24~₹50 crores
CAPEX guidance, FY24~₹100 crores total